In the recent clinical trials involving Chimeric Antigen Receptor T cell therapy (CAR-T), which complication led to a halt in the studies? A. Myocardial infarction B. Disseminated intravascular coagulation C. …
StatPearls Question of the Week – #5 Read More
February 6, 2017 (The Journal of Clinical Investigation) Part of the reason why treatment of solid tumors using CAR T-cells has been troublesome is because of adenosine production. Production of …
Targeting Adenosine 2A Receptors Enhances CAR T-Cell Efficacy Read More
January 26, 2017 (HealthDay News) Modified T cells from healthy donor allowed infants to reach remission, researchers report Two infants with B-cell acute lymphoblastic leukemia (ALL) are in remission after …
Universal CAR T-Cell Therapy Helped Treat ALL in Two Infants Read More
May 22, 2017 (Medical News Today) An antibody originally developed to study multiple sclerosis has been found to precisely target T cells that can kill cancer cells. Researchers at Brigham …
Antibody That Precisely Targets T Cells Discovered Read More On which malignancies is Chimeric Antigen Receptor T-cell therapy (CAR-T) being tested? A. Solid tumors B. Hematological malignancies C. Sarcomas D. Skin cancers Click for the answer and teaching points.
StatPearls Question of the Week – #4 Read More
CAR T-Cell Therapy and Checkpoint Inhibitors Together? CAR T-cell therapy positive response rates in aggressive leukemias and lymphomas are impressive, but relapse or progression does occur in some patients after …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 6 Trials Read More
CAR T-Cell Therapy for ALL Axicabtagene ciloleucel (KTE-C19) is also being investigated in the ZUMA-3 and ZUMA-4 trials for treatment of relapsed/refractory acute lymphoblastic leukemia (r/r ALL) in adult and …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 3 & 4 Trials Read More
ZUMA-2 Trial: Mantle Cell Lymphoma In the ZUMA-2 trial, Kite Pharma is also evaluating the treatment of relapsed/refractory mantle cell lymphoma (MCL) with KTE-C19. MCL is an aggressive B-cell lymphoma …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 2 Trials Read More
Hematologic Cancers: On Deck for CAR T Emerging immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies are some of the most exciting new investigational agents in oncology today. Clinical …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 1 Trials Read More From the early clinical trials involving chimeric antigen receptor T cell therapy (CAR-T), cytokine release syndrome has been a major problem. To block the high levels of interleukin 6, what …
StatPearls Question of the Week – #3 Read More